Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Transderm, OSU, UMass, and More


Title: Lentiviral Transduced Dendritic Cells for RNAi

Patent Number: 8,530,153

Filed: March 10, 2011

Inventor: Sam Kam Pun Kung, University of Manitoba

"The invention provides methods to prepare and use lentivirus transduced mammalian dendritic cells with altered levels of T cell co-stimulatory molecules," the patent's abstract states.

Title: miR-29-based Methods for the Diagnosis and Prognosis of Acute Myeloid Leukemia

Patent Number: 8,530,159

Filed: Oct. 7, 2011

Inventor: Carlo Croce, Ohio State University

The invention provides "novel methods and compositions for the diagnosis, prognosis, and treatment of acute myeloid leukemia," the patent's abstract states. "The invention also provides methods of identifying anti-AML agents."

Title: Methods and Compositions for Transdermal Delivery of Nucleotides

Patent Number: 8,530,436

Filed: Jan. 29, 2007

Inventor: Roger Kaspar, Transderm

The invention, the patent's abstract states, relates to "formulations and related methods for transdermal delivery of nucleic acids. Specifically, the invention relates to a formulation containing lipids and an alcohol and which is capable of providing effective transdermal delivery of nucleic acid. The formulation can be used effectively to deliver nucleic acids for gene therapy and the treatment of disease."

Title: In Vivo Production of Small Interfering RNAs that Mediate Gene Silencing

Patent Number: 8,530,438

Filed: March 19, 2010

Lead Inventor: Phillip Zamore, University of Massachusetts

The invention, the patent's abstract states, provides "engineered RNA precursors that, when expressed in a cell, are processed by the cell to produce targeted small interfering RNAs that selectively silence targeted genes (by cleaving specific mRNAs) using the cell's own RNA interference pathway. By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially."

Title: dsRNA Delivery Composition and Methods of Use

Patent Number: 8,530,440

Filed: May 3, 2011

Lead Inventor: Blair Siegfried, University of Nebraska

The invention, the patent's abstract states, relates to "compositions comprising a cucurbitacin bait for stimulating insect feeding and a dsRNA … for eliciting RNAi-mediated gene silencing in an insect. The … invention also provides for methods of delivering a dsRNA molecule to an insect, inhibiting protein expression in an insect, and killing an insect by providing a dsRNA molecule."

Title: miR-150 for the Treatment of Blood Disorders

Patent Number: 8,530,443

Filed: Oct. 16, 2012

Lead Inventor: Jun Lu, Massachusetts Institute of Technology

"The invention provides methods of treating certain blood related disorders, in particular, thrombocytopenia and anemia comprising increasing miR-150 expression or inhibiting miR-150 in progenitor cells respectively," according to the patent's abstract.

Title: Methods and Systems for Identifying microRNA Targets and Synthesizing Novel microRNAs and Uses of the Same

Patent Number: 8,532,937

Filed: Feb. 22, 2012

Lead Inventor: Artemis Hatzigeorgiou, University of Pennsylvania

The invention, the patent's abstract states, comprises methods of "identifying a microRNA-recognition element and of generating microRNAs … [as well as a] system and computer programs for performing such methods."